Sonnet BioTherapeutics I...

1.33
0.06 (4.72%)
At close: Apr 02, 2025, 3:59 PM
1.36
2.35%
After-hours: Apr 02, 2025, 04:35 PM EDT

Sonnet BioTherapeutics Statistics

Share Statistics

Sonnet BioTherapeutics has 3.07M shares outstanding. The number of shares has increased by -1.5% in one year.

Shares Outstanding 3.07M
Shares Change (YoY) -1.5%
Shares Change (QoQ) 1.94%
Owned by Institutions (%) 0.05%
Shares Floating 3.03M
Failed to Deliver (FTD) Shares 135
FTD / Avg. Volume 0.1%

Short Selling Information

The latest short interest is 40.12K, so 1.33% of the outstanding shares have been sold short.

Short Interest 40.12K
Short % of Shares Out 1.33%
Short % of Float 1.35%
Short Ratio (days to cover) 0.03

Valuation Ratios

The PE ratio is -0.59 and the forward PE ratio is -0.12. Sonnet BioTherapeutics's PEG ratio is 0.02.

PE Ratio -0.59
Forward PE -0.12
PS Ratio 235.35
Forward PS 1193.6
PB Ratio -9.02
P/FCF Ratio -0.51
PEG Ratio 0.02
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Sonnet BioTherapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 0.66, with a Debt / Equity ratio of -0.27.

Current Ratio 0.66
Quick Ratio 0.66
Debt / Equity -0.27
Debt / EBITDA -0.01
Debt / FCF -0.02
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $1.43K
Profits Per Employee $-572.09K
Employee Count 13
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -91.5% in the last 52 weeks. The beta is 1.01, so Sonnet BioTherapeutics's price volatility has been higher than the market average.

Beta 1.01
52-Week Price Change -91.5%
50-Day Moving Average 1.51
200-Day Moving Average 4.15
Relative Strength Index (RSI) 39.75
Average Volume (20 Days) 136.48K

Income Statement

In the last 12 months, Sonnet BioTherapeutics had revenue of 18.63K and earned -7.44M in profits. Earnings per share was -11.35.

Revenue 18.63K
Gross Profit 18.63K
Operating Income -11.85M
Net Income -7.44M
EBITDA -11.85M
EBIT -11.85M
Earnings Per Share (EPS) -11.35
Full Income Statement

Balance Sheet

The company has 149.46K in cash and 130.86K in debt, giving a net cash position of 18.59K.

Cash & Cash Equivalents 149.46K
Total Debt 130.86K
Net Cash 18.59K
Retained Earnings -117.68M
Total Assets 7.18M
Working Capital 3.6M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -8.61M and capital expenditures 0, giving a free cash flow of -8.61M.

Operating Cash Flow -8.61M
Capital Expenditures 0
Free Cash Flow -8.61M
FCF Per Share -13.14
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -63617.91% and -39929.3%.

Gross Margin 100%
Operating Margin -63617.91%
Pretax Margin -39929.3%
Profit Margin -39929.3%
EBITDA Margin -63617.91%
EBIT Margin -63617.91%
FCF Margin -46213.48%

Dividends & Yields

SONN does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for SONN is $38, which is 2757.1% higher than the current price. The consensus rating is "Buy".

Price Target $38
Price Target Difference 2757.1%
Analyst Consensus Buy
Analyst Count 2
Stock Forecasts

Stock Splits

The last stock split was on Sep 30, 2024. It was a backward split with a ratio of 1:8.

Last Split Date Sep 30, 2024
Split Type backward
Split Ratio 1:8

Scores

Altman Z-Score -28.22
Piotroski F-Score 5